Research progress of clarithromycin resistance mechanism of rapidly growing mycobacteria

Abstract

WU Bi-tong，TAN Shou-yong，CAI Xing-shan，KUANG Xiao-jia. Research progress of clarithromycin resistance mechanism of rapidly growing mycobacteria[J]. Chinese Journal of Antituberculosis, 2012, 34(10): 681-683.

References

［1］Sakatani M. Nontuberculous mycobacteriosis；the present status of epidemiology and clinical studies. Kekkaku,1999,74(4):377-384.

［2］Jarzembowski JA, Young MB. Nontuberculous mycobacterial infections. Arch Pathol Lab Med,2008,132(8):1333-1341.

［3］Witebsky FG, Conville PS. Rapidly growing mycobacteria. In: Borriello PS, Murray PR, Funke G,eds. Topley and Wilson’s Microbiology and Microbial Infections:Bacteriology Volume 2. London: Hodder Arnold，2005:1234-1269.

［4］Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev,2002,15（4）:716-746.

［5］Petrini B. Mycobacterium abscessus: an emerging rapid-growing potential pathogen. APMIS,2006,114(5):319-328.

［6］Adékambi T, Drancourt M. Mycobacterium bolletii respiratory infections. Emerg Infect Dis,2009,15(2):302-305.

［7］Yang SC, Hsueh PR, Lai HC, et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother,2003,47(6)：1958-1962.

［8］Huang TS, Lee SS, Hsueh PR, et al. Antimicrobial resistance of rapidly growing mycobacteria in western Taiwan: SMART program 2002. J Formos Med Assoc，2008, 107(4):281-287.

［9］Jamal MA, Maeda S, Nakata N, et al. Molecular basis of clarithromycin-resistance in Mycobacterium avium intracellulare complex. Tuber Lung Dis, 2000, 80(1):1-4.

［10］Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev， 2006，19（2）:382-402.

［11］Nikaido H. Multidrug resistance in bacteria. Annu Rev Biochem，2009，78:119-146.

［12］Ortíz-Pérez A, Martín-de-Hijas N, Alonso-Rodríguez N, et al. Importance of antibiotic penetration in the antimicrobial resistance of biofilm formed by non-pigmented rapidly growing mycobacteria against amikacin, ciprofloxacin and clarithromycin. Enferm Infecc Microbiol Clin，2011,29(2):79-84.

［13］Vugia DJ, Jang Y, Zizek C,et al. Mycobacteria in nail salon whirlpool footbaths, California. Emerg Infect Dis,2005,11(4):616-618.

［14］Nash KA, Zhang Y, Brown-Elliott BA, et al. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother， 2005, 55(2):170-177.

［15］Poole K. Efflux-mediated antimicrobial resistance. J Antimicrobial Chemother，2005, 56 (1): 20-51.

［16］Prado AC, Castillo PF. Lay clinics and an epidemic outbreak of mycobacterium skin and soft-tissue infection. Plast Reconstr Surg, 2004, 113(2):800-801.

［17］刘军,李良成,扈庆华,等. 53株龟分枝杆菌脓肿亚种临床分离株的药敏试验研究.中国卫生检验杂志,2000,10(4):407-408.

［18］Chopra S, Matsuyama K, Hutson C, et al. Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. J Antimicrob Chemother，2011,66(7):1533-1536.

［19］Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med, 2009, 180(9):896-902.

［20］Wallace RJ Jr, Meier A, Brown BA, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother,1996，40（7）:1676-1681.

［21］Bastian S, Veziris N, Roux AL, et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother, 2011,55(2):775-781.

［22］沙巍,翁心华,肖和平,等.脓肿分支杆菌耐利福平及rpoB基因突变情况的研究.中华结核和呼吸杂志,2003,26(9):544-547.

［23］Wallace RJ Jr, Brown BA, Onyi GO. Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid.Antimicrob Agents Chemother, 1991, 35(4):773-775.

［24］Wallace RJ Jr, Hull SI, Bobey DG, et al. Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei. Evidence is based on plasmid analysis, mutational frequencies, and aminoglycoside-modifying enzyme assays. Am Rev Respir Dis, 1985,132(2):409-416.

［25］Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother, 2009, 53(4): 1367-1376.

［26］DeRyke CA, Lee SY, Kuti JL, et al. Optimising dosing strategies of antibacterials utilizing pharmacodynamic principles: impact on the development of resistance. Drugs, 2006,66(1):1-14.